ARVO 2026: Optogenetic REMAIN 3 year study data

Key Takeaways

• A synthetic opsin-like protein is introduced via intravitreal injection to confer light sensitivity to surviving retinal cells in retinitis pigmentosa.
• Functional improvements ranged from light perception to hand-motion, with a best-case shift from 20/1,700, indicating potential utility in end-stage disease.
• The trial achieved a primary endpoint of ≥3-line letter gain and maintained benefit for three years, supporting durability of effect.
• No serious adverse events were reported, suggesting an acceptable safety profile for an intravitreal gene-therapy delivery strategy.
• Gene-agnostic positioning enables potential applicability to other advanced photoreceptor-loss conditions, including Stargardt disease and late geographic atrophy.